ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber Sells 17,238 Shares

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 17,238 shares of ProKidney stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $2.50, for a total value of $43,095.00. Following the transaction, the senior vice president now owns 172,432 shares of the company’s stock, valued at approximately $431,080. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

ProKidney Stock Performance

Shares of ProKidney stock traded up $0.12 on Wednesday, hitting $2.84. The company’s stock had a trading volume of 3,434,136 shares, compared to its average volume of 641,363. ProKidney Corp. has a 1 year low of $1.12 and a 1 year high of $13.51. The firm has a fifty day moving average price of $1.56 and a 200-day moving average price of $1.80. The company has a market capitalization of $651.33 million, a price-to-earnings ratio of -4.98 and a beta of 1.08.

ProKidney (NASDAQ:PROK) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.10. As a group, analysts forecast that ProKidney Corp. will post -0.65 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on PROK. Morgan Stanley began coverage on ProKidney in a research note on Thursday, March 7th. They issued an “equal weight” rating and a $3.00 price target for the company. Bank of America lowered ProKidney from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 2nd.

Institutional Investors Weigh In On ProKidney

Institutional investors have recently bought and sold shares of the company. Lazard Asset Management LLC acquired a new stake in ProKidney in the 2nd quarter worth about $31,000. Tower Research Capital LLC TRC boosted its holdings in shares of ProKidney by 98.5% during the 1st quarter. Tower Research Capital LLC TRC now owns 4,456 shares of the company’s stock worth $50,000 after purchasing an additional 2,211 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new position in shares of ProKidney during the 2nd quarter worth approximately $57,000. UBS Group AG boosted its holdings in shares of ProKidney by 97.5% during the 1st quarter. UBS Group AG now owns 5,209 shares of the company’s stock worth $59,000 after purchasing an additional 2,571 shares during the last quarter. Finally, Royal Bank of Canada boosted its holdings in shares of ProKidney by 530.3% during the 2nd quarter. Royal Bank of Canada now owns 6,965 shares of the company’s stock worth $78,000 after purchasing an additional 5,860 shares during the last quarter. 51.59% of the stock is currently owned by institutional investors and hedge funds.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.